TECHNEUTRAL

TECH EV/EBITDA Analysis

34.0x

Higher than 88% of Healthcare sector peers

Updated 1115h ago·SEC filings & market data

Key Takeaway

EV/EBITDA measures how many years of pre-tax cash earnings it would take to buy the entire company, including debt.

Sector Performance

88th percentile

TECH

34.0x

Sector Median

16.8x

Sector Avg

29.3x

Prior Period

31.9x(Aug 2026)

↓ Declining

📊

Deep Analysis

EV/EBITDA measures how many years of pre-tax cash earnings it would take to buy the entire company, including debt.

At 31.9x, Bio-Techne's valuation is nearly double the sector median of 16.1x, placing it in the 88th percentile of healthcare peers. The metric has been stable over the last eight quarters, with a year-over-year increase of 3.4% and a quarter-over-quarter increase of 2.7%. High valuation combined with a stable trend suggests the market is pricing in continued premium performance, leaving limited cushion if growth misses expectations. That combination implies moderate downside risk rather than an immediate opportunity. This aligns with the overall NEUTRAL verdict: the rich multiple isn't improving enough to justify bullishness, nor deteriorating enough to call for bearishness.

Frequently Asked Questions

What does the EV/EBITDA tell investors about TECH?

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.

How is the EV/EBITDA calculated?

EV/EBITDA is calculated as: Enterprise Value / EBITDA.

How does TECH's EV/EBITDA compare to its sector?

TECH's EV/EBITDA of 34.0x compares to a Healthcare sector median of 16.8x, placing it in the 88th percentile.

Who are TECH's closest peers by EV/EBITDA?

The closest Healthcare peers by EV/EBITDA include: RVTY (19.2x), CAH (14.4x), DGX (14.3x), ABT (19.5x), AMGN (14.0x).

📚

Learn More About EV/EBITDA

EV/EBITDA Explained: The Valuation Metric Pro Investors Actually Use

Learn what EV/EBITDA is, why it beats P/E for capital-heavy companies, typical sector ranges, and key limitations every serious investor should know.

The Formula

Enterprise Value / EBITDA

Why It Matters

A valuation multiple preferred by analysts for capital-intensive or leveraged businesses. Useful for cross-sector comparisons where earnings can be distorted by debt.